<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24086334</article-id><article-id pub-id-type="pmc">3783434</article-id><article-id pub-id-type="publisher-id">PONE-D-13-21158</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0074316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A Single Dose of Azithromycin Does Not Improve Clinical Outcomes of Children Hospitalised with Bronchiolitis: A Randomised, Placebo-Controlled Trial</article-title><alt-title alt-title-type="running-head">Azithromycin to Treat Hospitalised Bronchiolitis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McCallum</surname><given-names>Gabrielle B.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Peter S.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chatfield</surname><given-names>Mark D.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Maclennan</surname><given-names>Carolyn</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Andrew V.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sloots</surname><given-names>Theo P.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mackay</surname><given-names>Ian M.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Anne B.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Paediatrics, The Townsville Hospital, Townsville, Queensland, Australia</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Queensland Paediatric Infectious Diseases Laboratory, Sir Albert Sakzewski Virus Research Centre, Queensland Children's Medical Research Institute, Children's Health Queensland Hospital and Health Service, The University of Queensland, Brisbane, Australia</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Queensland Children's Respiratory Centre, Royal Children's Hospital, Brisbane, Queensland, Queensland University of Technology, Kelvin Grove, Australia</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Sawada</surname><given-names>Hideyuki</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>National Hospital of Utano, Japan</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>Gabrielle.McCallum@menzies.edu.au</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: AC PM CM. Performed the experiments: GBM CM AW. Analyzed the data: GBM MC. Contributed reagents/materials/analysis tools: GBM MC AC PM IM TS CM AW. Wrote the paper: GBM AC PM MC IM TS CM AW. Set up and coordinated the study, managed the project, performed the data analysis and drafted the manuscript: GBM. Conceptualised the study, was responsible for obtaining the grants, interpreted the data and edited the manuscript: AC. Assisted in study design and data interpretation and contributed to the manuscript: PM. Responsible for standardising the management of bronchiolitis in their units, recruiting participants and edited the manuscript: CM AW. Assisted in the viral components of the study and the manuscript: TS IM. Assisted in the data analysis and edited the manuscript: MC. Read and approved the final manuscript: GBM PM MC CM AW TS IM AC.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2013</year></pub-date><volume>8</volume><issue>9</issue><elocation-id>e74316</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 McCallum et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>McCallum et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Bronchiolitis, one of the most common reasons for hospitalisation in young children, is particularly problematic in Indigenous children. Macrolides may be beneficial in settings where children have high rates of nasopharyngeal bacterial carriage and frequent prolonged illness. The aim of our double-blind placebo-controlled randomised trial was to determine if a large single dose of azithromycin (compared to placebo) reduced length of stay (LOS), duration of oxygen (O<sub>2</sub>) and respiratory readmissions within 6 months of children hospitalised with bronchiolitis. We also determined the effect of azithromycin on nasopharyngeal microbiology.</p></sec><sec><title>Methods</title><p>Children aged &#x02264;18 months were randomised to receive a single large dose (30 mg/kg) of either azithromycin or placebo within 24 hrs of hospitalisation. Nasopharyngeal swabs were collected at baseline and 48hrs later. Primary endpoints (LOS, O<sub>2</sub>) were monitored every 12 hrs. Hospitalised respiratory readmissions 6-months post discharge was collected.</p></sec><sec><title>Results</title><p>97 children were randomised (n&#x0200a;=&#x0200a;50 azithromycin, n&#x0200a;=&#x0200a;47 placebo). Median LOS was similar in both groups; azithromycin&#x0200a;=&#x0200a;54 hours, placebo&#x0200a;=&#x0200a;58 hours (difference between groups of 4 hours 95%CI -8, 13, p&#x0200a;=&#x0200a;0.6). O<sub>2</sub> requirement was not significantly different between groups; Azithromycin&#x0200a;=&#x0200a;35 hrs; placebo&#x0200a;=&#x0200a;42 hrs (difference 7 hours, 95%CI -9, 13, p&#x0200a;=&#x0200a;0.7). Number of children re-hospitalised was similar 10 per group (OR&#x0200a;=&#x0200a;0.9, 95%CI 0.3, 2, p&#x0200a;=&#x0200a;0.8). At least one virus was detected in 74% of children. The azithromycin group had reduced nasopharyngeal bacterial carriage (p&#x0200a;=&#x0200a;0.01) but no difference in viral detection at 48 hours.</p></sec><sec><title>Conclusion</title><p>Although a single dose of azithromycin reduces carriage of bacteria, it is unlikely to be beneficial in reducing LOS, duration of O<sub>2</sub> requirement or readmissions in children hospitalised with bronchiolitis. It remains uncertain if an earlier and/or longer duration of azithromycin improves clinical and microbiological outcomes for children. The trial was registered with the Australian and New Zealand Clinical Trials Register. Clinical trials number: ACTRN12608000150347. <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/TrialSearch.aspx">http://www.anzctr.org.au/TrialSearch.aspx</ext-link>.</p></sec></abstract><funding-group><funding-statement>Study was funded by grants from the Channel 7 Foundation (seed funding 2007), the Financial Markets Foundation for Children (for 2 years), and supported by a National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children (grant number 1040830). GBM is supported by a NHMRC scholarship (grant 1055262), AC is funded by a NHMRC practitioner fellowship (grant 545216). The views expressed in this publication are those of the authors and do not reflect the views of any of the granting bodies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Worldwide, bronchiolitis remains one of the most common reasons for hospitalisation of children <xref rid="pone.0074316-Chang1" ref-type="bibr">[1]</xref>. Over 3 million children are diagnosed with bronchiolitis annually <xref rid="pone.0074316-Nair1" ref-type="bibr">[2]</xref>, <xref rid="pone.0074316-Ducharme1" ref-type="bibr">[3]</xref>. The incidence of bronchiolitis is higher in some populations, including Alaskan Native and Indigenous Northern Territory (NT) infants <xref rid="pone.0074316-Chang1" ref-type="bibr">[1]</xref>. In the latter group, hospitalisation rates for bronchiolitis are higher <xref rid="pone.0074316-OGrady1" ref-type="bibr">[4]</xref> (352 vs. 62.6 per 1000) and infections are more severe than non-Indigenous children <xref rid="pone.0074316-Bailey1" ref-type="bibr">[5]</xref>.</p><p>Bronchiolitis is a clinical syndrome that is diagnosed in children up to 24 months of age <xref rid="pone.0074316-Dawson1" ref-type="bibr">[6]</xref>&#x02013;<xref rid="pone.0074316-Subcommittee1" ref-type="bibr">[8]</xref>. The most common infecting virus, respiratory syncytial virus (RSV) occurs in 50&#x02013;80% of cases, <xref rid="pone.0074316-Zorc1" ref-type="bibr">[9]</xref> although an increasing number of viruses (e.g. human rhinoviruses (HRV), coronaviruses, bocavirus), <xref rid="pone.0074316-Jartti1" ref-type="bibr">[10]</xref>, <xref rid="pone.0074316-Brodzinski1" ref-type="bibr">[11]</xref> including multiple infections <xref rid="pone.0074316-ParanhosBaccala1" ref-type="bibr">[12]</xref> are being identified.</p><table-wrap id="pone-0074316-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.t001</object-id><label>Table 1</label><caption><title>Demographic and clinical characteristics of 96 patients randomized to treatment of Azithromycin (n&#x0200a;=&#x0200a;50) or placebo (n&#x0200a;=&#x0200a;46) and by ethnicity.</title></caption><alternatives><graphic id="pone-0074316-t001-1" xlink:href="pone.0074316.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Azithromycin (n&#x0200a;=&#x0200a;50)</td><td colspan="3" align="left" rowspan="1">Placebo (n&#x0200a;=&#x0200a;46)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Indigenous (31)</td><td align="left" rowspan="1" colspan="1">Non Indigenous (19)</td><td align="left" rowspan="1" colspan="1">TOTAL (50)</td><td align="left" rowspan="1" colspan="1">Indigenous (30)</td><td align="left" rowspan="1" colspan="1">Non Indigenous (16)</td><td align="left" rowspan="1" colspan="1">TOTAL (46)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age in months</td><td align="left" rowspan="1" colspan="1">5 (3&#x02013;8)</td><td align="left" rowspan="1" colspan="1">5.6 (1.5&#x02013;11)</td><td align="left" rowspan="1" colspan="1">5.3 (3&#x02013;9.4)</td><td align="left" rowspan="1" colspan="1">5.5 (3.1&#x02013;8.5)</td><td align="left" rowspan="1" colspan="1">5 (2.3&#x02013;8.5)</td><td align="left" rowspan="1" colspan="1">5 (3&#x02013;8.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x02264;6 months</td><td align="left" rowspan="1" colspan="1">19 (61%)</td><td align="left" rowspan="1" colspan="1">9 (47.3%)</td><td align="left" rowspan="1" colspan="1">28 (56%)</td><td align="left" rowspan="1" colspan="1">18 (60%)</td><td align="left" rowspan="1" colspan="1">9 (53%)</td><td align="left" rowspan="1" colspan="1">27 (59%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Boys</td><td align="left" rowspan="1" colspan="1">23 (74%)</td><td align="left" rowspan="1" colspan="1">11 (58%)</td><td align="left" rowspan="1" colspan="1">34 (68%)</td><td align="left" rowspan="1" colspan="1">19 (63%)</td><td align="left" rowspan="1" colspan="1">12 (75%)</td><td align="left" rowspan="1" colspan="1">31 (67%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gestational age (weeks)</td><td align="left" rowspan="1" colspan="1">39 (35&#x02013;40)</td><td align="left" rowspan="1" colspan="1">38.3 (37&#x02013;40)</td><td align="left" rowspan="1" colspan="1">39 (36&#x02013;40)</td><td align="left" rowspan="1" colspan="1">38 (36&#x02013;39.1)</td><td align="left" rowspan="1" colspan="1">39.2 (38.1&#x02013;40)</td><td align="left" rowspan="1" colspan="1">38 (36&#x02013;40)</td></tr><tr><td align="left" rowspan="1" colspan="1">Birth weight (kg)</td><td align="left" rowspan="1" colspan="1">3.15 (1.9&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">3.38 (2.87&#x02013;3.78)</td><td align="left" rowspan="1" colspan="1">3.1 (2.5&#x02013;3.6)</td><td align="left" rowspan="1" colspan="1">2.82 (2.32&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">3.36 (2.72&#x02013;3.46)</td><td align="left" rowspan="1" colspan="1">2.87 (36&#x02013;40)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number from remote areas</td><td align="left" rowspan="1" colspan="1">19 (61%)</td><td align="left" rowspan="1" colspan="1">4 (21%)</td><td align="left" rowspan="1" colspan="1">23 (46%)</td><td align="left" rowspan="1" colspan="1">26 (87%)</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">29 (63%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Currently breastfed</td><td align="left" rowspan="1" colspan="1">11 (35%)</td><td align="left" rowspan="1" colspan="1">13 (68%)</td><td align="left" rowspan="1" colspan="1">24 (48%)</td><td align="left" rowspan="1" colspan="1">7 (23%)</td><td align="left" rowspan="1" colspan="1">7 (44%)</td><td align="left" rowspan="1" colspan="1">14 (63%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mother smoked during pregnancy</td><td align="left" rowspan="1" colspan="1">20 (65%)</td><td align="left" rowspan="1" colspan="1">2 (11%)</td><td align="left" rowspan="1" colspan="1">22 (44%)</td><td align="left" rowspan="1" colspan="1">17 (57%)</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">20 (43.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Exposed to household smoke</td><td align="left" rowspan="1" colspan="1">20 (65%)</td><td align="left" rowspan="1" colspan="1">3 (16%)</td><td align="left" rowspan="1" colspan="1">23 (46%)</td><td align="left" rowspan="1" colspan="1">24 (80%)</td><td align="left" rowspan="1" colspan="1">5 (31%)</td><td align="left" rowspan="1" colspan="1">29 (63%)</td></tr><tr><td colspan="7" align="left" rowspan="1">Symptoms present upon admission</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasal discharge</td><td align="left" rowspan="1" colspan="1">27 (87%)</td><td align="left" rowspan="1" colspan="1">16 (84%)</td><td align="left" rowspan="1" colspan="1">43 (86%)</td><td align="left" rowspan="1" colspan="1">23 (77%)</td><td align="left" rowspan="1" colspan="1">13 (81%)</td><td align="left" rowspan="1" colspan="1">36 (78%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cough</td><td align="left" rowspan="1" colspan="1">31 (100%)</td><td align="left" rowspan="1" colspan="1">19 (100%)</td><td align="left" rowspan="1" colspan="1">50 (100%)</td><td align="left" rowspan="1" colspan="1">30 (100%)</td><td align="left" rowspan="1" colspan="1">16 (100%)</td><td align="left" rowspan="1" colspan="1">46 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Breathing difficulties</td><td align="left" rowspan="1" colspan="1">31 (100%)</td><td align="left" rowspan="1" colspan="1">19 (100%)</td><td align="left" rowspan="1" colspan="1">50 (100%)</td><td align="left" rowspan="1" colspan="1">29 (97%)</td><td align="left" rowspan="1" colspan="1">16 (94%)</td><td align="left" rowspan="1" colspan="1">44 (96%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Poor feeding</td><td align="left" rowspan="1" colspan="1">15 (48%)</td><td align="left" rowspan="1" colspan="1">15 (79%)</td><td align="left" rowspan="1" colspan="1">30 (60%)</td><td align="left" rowspan="1" colspan="1">10 (33%)</td><td align="left" rowspan="1" colspan="1">16 (100%)</td><td align="left" rowspan="1" colspan="1">26 (57%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lethargy</td><td align="left" rowspan="1" colspan="1">16 (52%)</td><td align="left" rowspan="1" colspan="1">11 (58%)</td><td align="left" rowspan="1" colspan="1">27 (54%)</td><td align="left" rowspan="1" colspan="1">19 (63%)</td><td align="left" rowspan="1" colspan="1">11 (69%)</td><td align="left" rowspan="1" colspan="1">30 (65%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever &#x000b0;C</td><td align="left" rowspan="1" colspan="1">37 (36.3&#x02013;37.2)</td><td align="left" rowspan="1" colspan="1">37 (36&#x02013;37)</td><td align="left" rowspan="1" colspan="1">37 (36.2&#x02013;37.1)</td><td align="left" rowspan="1" colspan="1">37 (36.3&#x02013;37)</td><td align="left" rowspan="1" colspan="1">37 (36.3&#x02013;38)</td><td align="left" rowspan="1" colspan="1">37 (36.3&#x02013;37.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotics prescribed</td><td align="left" rowspan="1" colspan="1">27 (87%)</td><td align="left" rowspan="1" colspan="1">9 (47%)</td><td align="left" rowspan="1" colspan="1">36 (72%)</td><td align="left" rowspan="1" colspan="1">25 (83%)</td><td align="left" rowspan="1" colspan="1">7 (44%)</td><td align="left" rowspan="1" colspan="1">32 (70%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Supplemental IV fluid administered</td><td align="left" rowspan="1" colspan="1">12 (39%)</td><td align="left" rowspan="1" colspan="1">7 (37%)</td><td align="left" rowspan="1" colspan="1">19 (38%)</td><td align="left" rowspan="1" colspan="1">12 (40%)</td><td align="left" rowspan="1" colspan="1">7 (44%)</td><td align="left" rowspan="1" colspan="1">19 (41%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CXR taken</td><td align="left" rowspan="1" colspan="1">30 (97%)</td><td align="left" rowspan="1" colspan="1">14 (74%)</td><td align="left" rowspan="1" colspan="1">44 (54%)</td><td align="left" rowspan="1" colspan="1">27 (90%)</td><td align="left" rowspan="1" colspan="1">11 (69%)</td><td align="left" rowspan="1" colspan="1">38 (46%)</td></tr><tr><td colspan="7" align="left" rowspan="1">Co morbidities</td></tr><tr><td align="left" rowspan="1" colspan="1">Otitis Media</td><td align="left" rowspan="1" colspan="1">7 (23%)</td><td align="left" rowspan="1" colspan="1">5 (26%)</td><td align="left" rowspan="1" colspan="1">12 (24%)</td><td align="left" rowspan="1" colspan="1">3 (10%)</td><td align="left" rowspan="1" colspan="1">1 (6%)</td><td align="left" rowspan="1" colspan="1">4 (9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin infection</td><td align="left" rowspan="1" colspan="1">8 (26%)</td><td align="left" rowspan="1" colspan="1">2 (11%)</td><td align="left" rowspan="1" colspan="1">10 (20%)</td><td align="left" rowspan="1" colspan="1">9 (30%)</td><td align="left" rowspan="1" colspan="1">1 (6%)</td><td align="left" rowspan="1" colspan="1">10 (22%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anaemia</td><td align="left" rowspan="1" colspan="1">7 (23%)</td><td align="left" rowspan="1" colspan="1">1 (5%</td><td align="left" rowspan="1" colspan="1">8 (16%)</td><td align="left" rowspan="1" colspan="1">2 (7%)</td><td align="left" rowspan="1" colspan="1">1 (6%)</td><td align="left" rowspan="1" colspan="1">3 (7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Failure to Thrive</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0 (%)</td><td align="left" rowspan="1" colspan="1">1 (2%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0 (%)</td><td align="left" rowspan="1" colspan="1">1 (2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lobar Pneumonia/Collapse on CXR</td><td align="left" rowspan="1" colspan="1">8 (26%)</td><td align="left" rowspan="1" colspan="1">1 (5%)</td><td align="left" rowspan="1" colspan="1">9 (18%)</td><td align="left" rowspan="1" colspan="1">5 (17%)</td><td align="left" rowspan="1" colspan="1">0 (%)</td><td align="left" rowspan="1" colspan="1">5 (11%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">1 (2%)</td><td align="left" rowspan="1" colspan="1">3 (13%)</td><td align="left" rowspan="1" colspan="1">2 (13%)</td><td align="left" rowspan="1" colspan="1">6 (13%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>
<bold>Median and IQR (25&#x02013;75) for continuous variables. Actual numbers for categorical variables and percentages.</bold>
</p></fn><fn id="nt102"><label/><p>
<bold>NB</bold>: Missing variables described.</p></fn><fn id="nt103"><label/><p>
<bold>Azithromycin</bold>: Gestational age &#x0200a;=&#x0200a;3 (6%). Birth weight &#x0200a;=&#x0200a;6 (12%). Mother smoked during pregnancy &#x0200a;=&#x0200a;3 (6%). Exposure to household smoke &#x0200a;=&#x0200a;2 (4%), <bold>Placebo</bold>: Gestational age: &#x0200a;=&#x0200a;2 (4%). Birth weight &#x0200a;=&#x0200a;3 (6.5%).</p></fn><fn id="nt104"><label/><p>
<bold>Indigenous children</bold>: Gestational age &#x0200a;=&#x0200a;2 (3.3%). Birth weight &#x0200a;=&#x0200a;4 (6.5%). Mother smoked during pregnancy &#x0200a;=&#x0200a;2 (3%). Exposure to household smoke &#x0200a;=&#x0200a;1 (1.6%): <bold>Non Indigenous children</bold>: Gestational age: &#x0200a;=&#x0200a;3 (8.6%). Birth weight &#x0200a;=&#x0200a;5 (14.3%) Mother smoked during pregnancy &#x0200a;=&#x0200a;1 (3%). Exposure to household smoke &#x0200a;=&#x0200a;1 (3%).</p></fn></table-wrap-foot></table-wrap><p>Current recommended therapies in hospitalised children are limited to oxygen (O<sub>2</sub>), fluids and hypertonic saline nebulisation <xref rid="pone.0074316-Baumer1" ref-type="bibr">[7]</xref>. Antibiotics are rarely advocated in the management of bronchiolitis unless the illness is very severe or when a secondary bacterial infection is suspected <xref rid="pone.0074316-Spurling1" ref-type="bibr">[13]</xref>. However, semi-synthetic macrolides (e.g. azithromycin, clarithromycin) which have immuno-modulatory, and/or anti-microbial properties <xref rid="pone.0074316-Klein1" ref-type="bibr">[14]</xref> and <italic>in-vitro</italic> anti-viral effects, <xref rid="pone.0074316-GiamarellosBourboulis1" ref-type="bibr">[15]</xref> which may be beneficial in children with bronchiolitis and high nasopharyngeal carriage rates of bacteria. Three randomised placebo-controlled trials (RCTs) have been published and these RCTs used different doses and duration of macrolides to treat hospitalised bronchiolitis <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref>
<xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref>, <xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref>. These studies also differed in affluence of settings which may reflect differences in the frequency and severity of acute respiratory infections in these populations <xref rid="pone.0074316-Singleton1" ref-type="bibr">[19]</xref>. Thus not surprisingly, results from the existing RCTs differed in the effect on reducing length of hospitalisation and O<sub>2</sub> requirement. A Turkish <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> trial reported improved clinical outcomes. In comparison a European <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref> and a Brazilian <xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref> trials showed no improvement.</p><p>Bacterial infections in children with RSV positive acute lower respiratory infections range from 3.5% to 31% <xref rid="pone.0074316-Nair1" ref-type="bibr">[2]</xref>, <xref rid="pone.0074316-Weber1" ref-type="bibr">[20]</xref>, <xref rid="pone.0074316-Ghafoor1" ref-type="bibr">[21]</xref>. The higher rate is more likely in less-affluent settings and/or with those with more severe disease <xref rid="pone.0074316-OGrady2" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0074316-Bezerra1" ref-type="bibr">[24]</xref>. Viral-bacterial co-infections are more likely when the upper airways are densely colonised with bacteria or during repeated infections <xref rid="pone.0074316-Didierlaurent1" ref-type="bibr">[25]</xref>. In the NT, children have early acquisition of bacteria in the nasal space <xref rid="pone.0074316-SmithVaughan1" ref-type="bibr">[26]</xref>. This is more likely to be similar to Turkey where high rates of pneumonia and bronchiectasis are also reported <xref rid="pone.0074316-OGrady2" ref-type="bibr">[22]</xref>. Thus, we conducted a RCT on children hospitalised with bronchiolitis. Our primary objective was to determine whether a single large dose of azithromycin (compared to placebo) reduced length of stay (LOS) and duration of O<sub>2</sub> requirement in children hospitalised with moderate to severe bronchiolitis. We also determined the influence of azithromycin on the incidence of respiratory readmissions and presence of bacteria and viruses in the nasopharynx.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>Our double-blinded, placebo-controlled, RCT was conducted at the Royal Darwin Hospital between June 2008 and December 2011 and The Townsville Hospital between October 2010 and December 2011.</p></sec><sec id="s2b"><title>Trial registration</title><p>The trial was registered with the Australian and New Zealand Clinical Trials Register. Clinical trials number: ACTRN12608000150347.</p></sec><sec id="s2c"><title>Ethics statement</title><p>The study was approved by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (HREC 07/60) and The Townsville Health Service District Human Research Ethics Committee (HREC/10/QTHS/9). Individual written informed consent was obtained from children's parents or legal guardian.</p></sec><sec id="s2d"><title>Participants</title><p>Children were enrolled if they were &#x02264;18 months, admitted with a clinical diagnosis of bronchiolitis (according to standardised hospital protocols; &#x02264;18 months, with cough and coryza, wheezing +/&#x02212; crackles, respiratory distress with both tachypnoea (respiratory rate &#x0003e;50 beats/min) and retractions), required supplemental O<sub>2</sub> and consented within 24 hrs of hospitalisation. Children were excluded if they had: severe disease (admitted to intensive care unit); chronic lung disease, congenital heart disease, contraindications to macrolide use (e.g. liver dysfunction, hypersensitivity), diarrhoea (&#x0003e;2 stools of watery consistency more than normal pattern), received macrolides (in last 7-days), or clinical and radiological features consistent with a primary diagnosis of pneumonia <xref rid="pone.0074316-Chang2" ref-type="bibr">[27]</xref> at time of randomisation.</p></sec><sec id="s2e"><title>Protocol and interventions used across both sites</title><p>Study staff visited the paediatric wards twice daily to assess newly admitted children. After consent, children were randomised to receive a single large dose of oral liquid azithromycin (30 mg/kg) or placebo suspension (equal volume). The placebo suspension was made up of confectioner's Sugar, Hydroxypropyl Cellulose, Xanthan Gum, Syloid 244, Sodium Phosphate Tribasic, Imitation Vanilla Creamy Flavour, Black Cherry Flavour, Quinine Sulphate (ground Quinate 300 mg Tablets). Children were managed by the paediatric team of each hospital according to the same clinical protocol for bronchiolitis (e.g. criteria for commencement and weaning of O<sub>2</sub>) that was standardised &#x0003e;6 months before commencement of the trial. Children were allowed to receive concurrent medications specified by the attending physician, except macrolide antibiotics. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0074316.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0074316.s002">Protocol S1</xref>.</p></sec><sec id="s2f"><title>Randomisation, allocation and blinding</title><p>Randomisation was stratified by age (&#x02264;6 or &#x0003e;6 months), ethnicity (Indigenous or non-Indigenous) and site (Darwin or Townsville). Randomisation was by computer generated permuted blocks and treatment allocation concealed by opaque stickers. Upon enrolment, children were assigned the next treatment on the appropriate stratified list. Neither the study team (researchers, hospital staff) nor parents were aware of the assigned treatment group until the end of the trial.</p><p>The placebo medication was manufactured by the Institute of Drug Technology Australia Limited (Melbourne, Victoria). It had a similar smell and taste to active azithromycin. Azithromycin (Pfizer, Australia) was repackaged by IDT. Both medications were prepared as powder in identical opaque bottles and sealed with an aluminium foil.</p></sec><sec id="s2g"><title>Clinical assessment and outcome measures</title><p>Standardised data collection forms were used to record demographic, medical history and clinical data from each child (table-1). This included O<sub>2</sub> requirement and level, respiratory rate, temperature and heart rate. Other therapies (intravenous fluids, antibiotics) and routine investigations (full blood count and chest x-ray) were also documented.</p><table-wrap id="pone-0074316-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.t002</object-id><label>Table 2</label><caption><title>Subgroup analysis of LOS and time on O<sub>2</sub> by ethnicity and age.</title></caption><alternatives><graphic id="pone-0074316-t002-2" xlink:href="pone.0074316.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Azithromycin</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Difference</td><td align="left" rowspan="1" colspan="1">95% CI</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(placebo-Azithromycin)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">
<bold>Length of Stay (LOS) median hours</bold>
</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Ethnicity</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;Indigenous</bold>
</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(&#x02212;13, 20)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;Non Indigenous</bold>
</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">(&#x02212;11, 13)</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Age</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;&#x0003c;6 months</bold>
</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">(&#x02212;18,19)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;&#x0003e;6 months</bold>
</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">(&#x02212;9, 11)</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Time on oxygen (O<sub>2</sub>) median hours</bold>
</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Ethnicity</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;Indigenous</bold>
</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(&#x02212;12, 22)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;Non Indigenous</bold>
</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(&#x02212;17, 12)</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Age</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;&#x0003c;6 months</bold>
</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(&#x02212;18,19)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02003;&#x0003e;6 months</bold>
</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">(&#x02212;9, 12)</td></tr></tbody></table></alternatives></table-wrap><p>Children enrolled in the study were assessed twice daily by the attending doctor (blinded and not an investigator) for clinical signs inconsistent with bronchiolitis and associated with known azithromycin side effects. Outcome measures were collected every 12 hours until the study endpoint was reached. The primary endpoints were: LOS for respiratory illness and duration of O<sub>2</sub> requirement. LOS was defined as time from admission to time for &#x02018;ready for discharge&#x02019; (Sp0<sub>2</sub> consistently &#x0003e;94% in air for &#x0003e;16 hrs) and feeding adequately. &#x02018;Ready for discharge&#x02019; differed from LOS, as discharge from hospital in our setting is often delayed due to other social factors, especially in children from remote Indigenous communities. Other outcomes were (i) any respiratory related readmissions within 6 months of discharge and (ii) identification of respiratory viruses and bacterial pathogens. Adverse events were monitored by study staff every 12 hours until discharge. Respiratory readmissions were collected from the medical charts; as there these children had no access to any other hospitals in the region, this is a reliable outcome.</p></sec><sec id="s2h"><title>Specimen collection and process</title><p>A nasopharyngeal swab (NPS) was taken prior to administration of study medication and 48 hrs later (or at discharge). NPS were placed in skim milk tryptone glucose glycerol broth media and were transferred on ice stored at &#x02212;80&#x000b0;C in accordance to published guidelines <xref rid="pone.0074316-Stubbs1" ref-type="bibr">[28]</xref>, <xref rid="pone.0074316-Hare1" ref-type="bibr">[29]</xref>.</p><p>Assessment for viruses and atypical bacteria were described previously <xref rid="pone.0074316-Arden1" ref-type="bibr">[30]</xref>&#x02013;<xref rid="pone.0074316-Arden2" ref-type="bibr">[32]</xref>. Nucleic acids were extracted from 0.2 ml of each NPS using the High Pure Viral Nucleic Acid kit (Roche Diagnostics, Australia), according to the manufacturer's instructions. Polymerase Chain Reaction (PCR) methods were used to detect RSV (A and B), adenovirus, parainfluenza (1, 2, 3), influenzavirus (A and B), HRV and enterovirus, coronaviruses, bocavirus type 1, human metapneumovirus (hMPV), KI (KIPyV) and WU (WUPyV) polyomaviruses, <italic>Chlamydophila pneumoniae</italic> and <italic>Mycoplasma pneumoniae</italic>. For bacterial analysis, NPS were thawed and 10 &#x000b5;L aliquots cultured overnight on selective media at 37&#x000b0;C in 5% CO<sub>2</sub>; identification of <italic>Streptococcus pneumoniae</italic>, <italic>Haemophilus influenzae</italic>, <italic>Moraxella catarrhalis</italic> and <italic>Staphylococcus aureus</italic> used established techniques as previously described <xref rid="pone.0074316-SmithVaughan1" ref-type="bibr">[26]</xref>, <xref rid="pone.0074316-Stubbs1" ref-type="bibr">[28]</xref>, <xref rid="pone.0074316-Hare2" ref-type="bibr">[33]</xref>.</p><table-wrap id="pone-0074316-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.t003</object-id><label>Table 3</label><caption><title>Bacteria outcomes at pre treatment (baseline) and post treatment (48 hours).</title></caption><alternatives><graphic id="pone-0074316-t003-3" xlink:href="pone.0074316.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Azithromycin</td><td colspan="2" align="left" rowspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Azi vs. Placebo</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">48 hours</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">48 hours</td><td align="left" rowspan="1" colspan="1">48 hours</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P value</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasal carriage of pathogens</td><td align="left" rowspan="1" colspan="1">N&#x0200a;=&#x0200a;49</td><td align="left" rowspan="1" colspan="1">N&#x0200a;=&#x0200a;34</td><td align="left" rowspan="1" colspan="1">N&#x0200a;=&#x0200a;46</td><td align="left" rowspan="1" colspan="1">N&#x0200a;=&#x0200a;37</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Streptococcus pneumoniae</italic>
</td><td align="left" rowspan="1" colspan="1">9 (18%)</td><td align="left" rowspan="1" colspan="1">2 (6%)</td><td align="left" rowspan="1" colspan="1">15 (33%)</td><td align="left" rowspan="1" colspan="1">7 (19%)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Haemophilus influenzae</italic>
</td><td align="left" rowspan="1" colspan="1">18 (37%)</td><td align="left" rowspan="1" colspan="1">3 (9%)</td><td align="left" rowspan="1" colspan="1">18 (39%)</td><td align="left" rowspan="1" colspan="1">10 (27%)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Moraxella catarrhalis</italic>
</td><td align="left" rowspan="1" colspan="1">21 (43%)</td><td align="left" rowspan="1" colspan="1">2 (6%)</td><td align="left" rowspan="1" colspan="1">16 (35%)</td><td align="left" rowspan="1" colspan="1">12 (32%)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Staphylococcus aureus</italic>
</td><td align="left" rowspan="1" colspan="1">4 (8%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">4 (9%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">1.00</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2i"><title>Statistical methods</title><p>We formally compared baseline characteristics of Indigenous vs. non-Indigenous children, with appropriate statistical tests. We did not formally do this between treatment groups in accordance with current CONSORT recommendations (available <ext-link ext-link-type="uri" xlink:href="http://www.consort-statement.org/consort-statement/13-19-results/item15_baseline-data/">http://www.consort-statement.org/consort-statement/13-19-results/item15_baseline-data/</ext-link>. Accessed 28<sup>th</sup> June 2013). Our pre-specified analysis plan, stated that non parametric methods be used if data were not normally distributed. Data were presented as medians and interquartile range (IQR) for LOS and O<sub>2.</sub> Differences between groups were tested using the Mann-Whitney test. A 95% confidence interval (CI) was obtained for the difference in medians between treatment groups <xref rid="pone.0074316-Douglas1" ref-type="bibr">[34]</xref>. Subgroup analysis was performed by ethnicity (Indigenous vs. non-Indigenous) and by age (&#x02264;6 and &#x0003e;6 months). Differences in proportions were tested with Fisher's exact test. We looked at time to readmission within 6 months of hospital discharge using Kaplan-Meier survival plots.</p></sec><sec id="s2j"><title>Sample size</title><p>We calculated that a total sample of 92 children (equal numbers of Indigenous and non-Indigenous children recruited) would provide 90% power to detect a difference in the mean LOS of 24 hrs between each treatment for each ethnic group at the 5% significance level assuming the standard deviation was 24 hrs in each group. This study was underpowered to detect differences in rates of readmission between treatment groups.</p></sec></sec><sec id="s3"><title>Results</title><p>We recruited 97 children and data from 96 children were analysed (<xref ref-type="fig" rid="pone-0074316-g001">Figure 1</xref>). The major reason why 450 children did not meet the inclusion criteria was they did not require supplemental O<sub>2</sub> or were admitted over the weekend. During recruitment, 21 children admitted into intensive care were excluded; 17 were Indigenous. One participant was excluded from the analysis of primary outcomes; they had received a macrolide in the previous 7 days (this child was randomised to placebo). This child was included in the analysis of secondary outcomes. Of the 96 remaining children, demographic and clinical characteristics were similar between the treatment groups (Table-1). No children received steroids during hospitalisation. Of the cohort, 10 children were previously hospitalised for a respiratory episode, all were Indigenous; 3 in azithromycin group and 7 in placebo group.</p><fig id="pone-0074316-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g001</object-id><label>Figure 1</label><caption><title>CONSORT trial overview.</title></caption><graphic xlink:href="pone.0074316.g001"/></fig><p>When data were grouped by ethnicity, a higher proportion of Indigenous children lived in remote areas (n&#x0200a;=&#x0200a;45, 74%; p&#x0200a;=&#x0200a;&#x0003c;0.001), were exposed to cigarette smoke during pregnancy (n&#x0200a;=&#x0200a;37, 61%; p&#x0200a;=&#x0200a;&#x0003c;0.001), or in their household (n&#x0200a;=&#x0200a;44, 72%; p&#x0200a;=&#x0200a;&#x0003c;0.001). They were more likely to have coexisting co-morbidities (i.e. skin infections (n&#x0200a;=&#x0200a;17, 28%; p&#x0200a;=&#x0200a;0.02) or secondary pneumonia (n&#x0200a;=&#x0200a;13, 21%; p&#x0200a;=&#x0200a;0.01). More Indigenous children (n&#x0200a;=&#x0200a;34, 56%, p&#x0200a;=&#x0200a;&#x0003c;0.001) received antibiotics prior to hospitalisation. The antibiotics given were ceftriaxone (n&#x0200a;=&#x0200a;14, 41%), procaine penicillin (n&#x0200a;=&#x0200a;7, 21%) and amoxicillin (n&#x0200a;=&#x0200a;5, 15%). In hospital, additional antibiotics were more often prescribed in Indigenous children (n&#x0200a;=&#x0200a;52, 85%, p&#x0200a;=&#x0200a;&#x0003c;0.001) (Table-1).</p><p>LOS was similar in both treatment groups. The median LOS in the azithromycin group was 54 hrs, compared to 58 hrs in the placebo group (difference between groups of 4 hrs, 95%CI &#x02212;8, 13, p&#x0200a;=&#x0200a;0.6), <xref ref-type="fig" rid="pone-0074316-g002">figure 2</xref>. The median time on O<sub>2</sub> in the azithromycin group was 35 hrs, compared to 42 hrs in the placebo group (i.e. reduction of 7 hrs 95%CI &#x02212;9, 13, p&#x0200a;=&#x0200a;0.7), <xref ref-type="fig" rid="pone-0074316-g003">figure 3</xref>. No child required admission into intensive care and there were no adverse or serious adverse events.</p><fig id="pone-0074316-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g002</object-id><label>Figure 2</label><caption><title>Length of stay (LOS) in hospital &#x02013; Azithromycin Vs Placebo and Ethnicity.</title></caption><graphic xlink:href="pone.0074316.g002"/></fig><fig id="pone-0074316-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g003</object-id><label>Figure 3</label><caption><title>Time on Oxygen (O<sub>2</sub>) in hospital &#x02013; Azithromycin Vs Placebo and Ethnicity.</title></caption><graphic xlink:href="pone.0074316.g003"/></fig><p>All children contributed to readmission data. There was no significant difference in the number of respiratory readmissions within 6 months (10 per group, OR&#x0200a;=&#x0200a;0.9, 95%CI 0.3, 2, p&#x0200a;=&#x0200a;0.8) or time to readmission (logrank p&#x0200a;=&#x0200a;0.9) between treatment groups (<xref ref-type="fig" rid="pone-0074316-g004">figure 4</xref>). 70% of children readmitted, were reported to have a wheeze-associated illness.</p><fig id="pone-0074316-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g004</object-id><label>Figure 4</label><caption><title>Time to first readmission &#x02013; Azithromycin Vs Placebo.</title></caption><graphic xlink:href="pone.0074316.g004"/></fig><p>Indigenous children (n&#x0200a;=&#x0200a;61) had longer LOS; median 59 hrs compared to 51 hrs in non-Indigenous children (n&#x0200a;=&#x0200a;35) (difference of 8 hrs, 95%CI -25, 1.5, p&#x0200a;=&#x0200a;0.07). This was similar with duration of O<sub>2</sub>; 43 hrs in Indigenous children and 35 hrs in non-Indigenous children (difference of 8 hrs 95%CI -22, 1.4, p&#x0200a;=&#x0200a;0.08). A higher proportion of Indigenous children were readmitted for a respiratory illness (n&#x0200a;=&#x0200a;16 (26%) compared to non-Indigenous children (n&#x0200a;=&#x0200a;4 (11%)), difference 15% (95%CI 0, 30%) p&#x0200a;=&#x0200a;0.05. Indigenous children were more likely to be re-hospitalised earlier (Indigenous n&#x0200a;=&#x0200a;16, non-Indigenous n&#x0200a;=&#x0200a;4, OR&#x0200a;=&#x0200a;2.8, 95% CI 0.9, 8.8), logrank p&#x0200a;=&#x0200a;0.08 (<xref ref-type="fig" rid="pone-0074316-g005">figure 5</xref>). There was no evidence that the difference in either LOS or O<sub>2</sub> between treatment groups varied according to ethnicity or age (table-2).</p><fig id="pone-0074316-g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g005</object-id><label>Figure 5</label><caption><title>Time to first readmission &#x02013; Indigenous Vs Non-Indigenous.</title></caption><graphic xlink:href="pone.0074316.g005"/></fig><sec id="s3a"><title>Viral and bacteria data</title><p>All but one child had a baseline NPS. NPS could not be obtained on all participants at 48 hrs due to discharge occurring during evenings or weekends. One participant's family withdrew consent for NPS.</p><p>At baseline, viruses were not detected in 23 (24%) participants. One or more virus was detected in 54 (56%) children. Two or more viruses were detected in 19 (20%) of children. RSV was the most common (n&#x0200a;=&#x0200a;48, 50%), followed by HRV (n&#x0200a;=&#x0200a;16, 17%), hMPV (n&#x0200a;=&#x0200a;5, 5%) and coronavirus (n&#x0200a;=&#x0200a;5, 5%). <xref ref-type="fig" rid="pone-0074316-g006">Figure 6</xref> depicts the frequency of virus detection at baseline and 48hrs. There was no reduction in the mean number of viruses detected per child from baseline to 48hrs; azithromycin 1.0 to 0.8 (95% CI &#x02212;0.2, 0.6, n&#x0200a;=&#x0200a;34), placebo 0.9 to 1.0 (95% CI &#x02212;0.3, 0.2, n&#x0200a;=&#x0200a;37).</p><fig id="pone-0074316-g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0074316.g006</object-id><label>Figure 6</label><caption><title>Frequency of viruses detected in NPS &#x02013; Baseline and 48 hours.</title></caption><graphic xlink:href="pone.0074316.g006"/></fig><p>Table-3 summarises NPS bacteria detected at baseline and 48 hrs. A reduction in the mean number of respiratory bacteria was detected per child; in the azithromycin group from 1.2 to 0.5 bacteria (difference 0.7 95%CI 0.25, 1.1, p&#x0200a;=&#x0200a;0.01), and zero change in the placebo group; 1.3 to 1.3 bacteria.</p><p>Compared to baseline NPS, children who received azithromycin alone (n&#x0200a;=&#x0200a;14) (i.e. received no additional antibiotics in hospital) were less likely to have <italic>S. pneumoniae</italic> (3/14, vs. 0/11), <italic>M. catarrhalis</italic> (5/14 vs. 1/11), <italic>H. influenzae</italic> (6/14 vs. 1/11), and <italic>Staphylococcus aureus</italic> (1/14 vs.0/11) at 48 hrs. 3/14 children did not have NPS at 48 hrs.</p></sec></sec><sec id="s4"><title>Discussion</title><p>We found that a large single dose of azithromycin (compared to placebo), did not have large clinical effects on LOS, length of O<sub>2</sub> requirement or readmission within 6 months of discharge. Azithromycin reduced the proportion of children with respiratory bacteria in their NPS but had no significant effect on viral detection by PCR.</p><p>Of the 3 published RCTs on macrolides to treat hospitalised children with bronchiolitis, <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref>&#x02013;<xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref> only one <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> reported improved clinical effects i.e. reduced LOS, duration of O<sub>2</sub> requirement and lower readmission rates. Our findings are similar to the other two trials <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref>, <xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref> showing that a single dose azithromycin does not shorten LOS and O<sub>2</sub> requirement. However, methodological differences among trials need to be considered. One of the larger trials <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref> included only children with RSV-confirmed bronchiolitis, thus limiting generalisation to bronchiolitis caused by other pathogens. Other differences included: age, ethnic populations, concurrent use of antibiotics, treatment practices and macrolide type, dose and duration. The immunomodulatory difference between azithromycin and clarithromycin may also account for the differential results between Tahan et al's study <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> with ours and the other 2 RCTs <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref>, <xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref>. For example, azithromycin increased the production of IL-10 whereas clarithromycin inhibited the production of IL-6 by dendritic cells in animal work <xref rid="pone.0074316-Sugiyama1" ref-type="bibr">[35]</xref>. Tahan and colleagues <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> used a daily dose for 3-weeks of clarithromycin, but ours like Kneyber et al <xref rid="pone.0074316-Kneyber1" ref-type="bibr">[16]</xref>, <xref rid="pone.0074316-Pinto1" ref-type="bibr">[18]</xref> (7-day daily dose) used a short course of azithromycin. However, Tahan et al's <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> study had very small numbers (n&#x0200a;=&#x0200a;21) and high attrition. Thus, it remains unknown if a longer course of azithromycin may be effective in reducing readmission rates.</p><p>Of the published RCTs on macrolides for bronchiolitis in children, our patient profile is most like that of the Turkish study <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref>. However, unlike the Turkish RCT, <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref> we did not find a beneficial effect of azithromycin on clinical outcomes. Possibly contributory reasons include the very high concomitant use of antibiotics in our group; different treatment regime used the density of bacterial carriage and secondary co-morbidities. The common use of antibiotics in children with bronchiolitis in our setting relates to the high rates of concomitant infections among children. A similar treatment practice occurs in Alaskan children <xref rid="pone.0074316-Chang1" ref-type="bibr">[1]</xref>. 56% of Indigenous children in our trial received antibiotics before admission and 87% during hospitalisation. While the use of antibiotics is common practice in such settings, its effectiveness and possibly increased adverse events remains unknown. Ideally concurrent antibiotics should have been disallowed in our study but it was not possible to alter clinicians' practice and our <italic>a priori</italic> protocol allowed the concurrent use of antibiotics other than macrolides.</p><p>We used a single large dose of azithromycin, which is equivalent to one week of treatment for several reasons <xref rid="pone.0074316-Blasi1" ref-type="bibr">[36]</xref>. In our setting, early (as early as 2-weeks of age) nasopharyngeal colonisation of respiratory pathogens occurs in Indigenous children <xref rid="pone.0074316-Leach1" ref-type="bibr">[37]</xref>. Azithromycin potentially has a beneficial microbiological effect on these pathogens <xref rid="pone.0074316-Blasi1" ref-type="bibr">[36]</xref>. Azithromycin also has the benefit of a long half life and tissue penetration requiring less frequent dosing, compared to other antibiotics <xref rid="pone.0074316-Blasi1" ref-type="bibr">[36]</xref>. This is important in our setting where adherence to treatment regimes can be challenging.</p><p>While our trial did not find significant differences between treatment groups for clinical outcomes, our study had some novel data. Firstly, none of the published RCTs on macrolides for children with bronchiolitis report data on the impact on viral detection or bacterial carriage. As viruses were identified by PCR, it is not surprising no difference in viral detection were found at 48 hrs (although azithromycin may have some anti-viral effect) <xref rid="pone.0074316-GiamarellosBourboulis1" ref-type="bibr">[15]</xref>. Future research should look at the impact of azithromycin on viral load/copies. While our numbers were small, we showed a significant difference in the mean number of respiratory bacteria per child; from 1.2 to 0.5 bacteria (difference 0.7 95%CI 0.25, 1.1, p&#x0200a;=&#x0200a;0.01) in the azithromycin group. This is important in our setting as NPS carriage of respiratory pathogens (e.g. <italic>S. pneumoniae, H. influenzae, M. catarrhalis</italic>) are among the highest reported globally (over 80%), compared to non-Indigenous children (50%) <xref rid="pone.0074316-SmithVaughan1" ref-type="bibr">[26]</xref>.</p><p>Secondly, our study provides a clinical picture of hospitalised cases of bronchiolitis in different geographical and ethnic groups in Northern Australia, where acute respiratory infections may be one precursor of high rates of chronic respiratory illness <xref rid="pone.0074316-Bailey1" ref-type="bibr">[5]</xref>, <xref rid="pone.0074316-OGrady3" ref-type="bibr">[38]</xref> This is the first data published, showing NPS detection of viruses and bacteria from Indigenous children hospitalised with bronchiolitis. Wheezing and bacterial infections in young children have been shown to be associated in one prospective cohort study <xref rid="pone.0074316-Bisgaard1" ref-type="bibr">[39]</xref>. Thus our data may have implications in settings, where acute and chronic respiratory diseases are particularly prevalent and more severe, including Alaska and New Zealand <xref rid="pone.0074316-Singleton2" ref-type="bibr">[40]</xref>&#x02013;<xref rid="pone.0074316-Grimwood1" ref-type="bibr">[42]</xref>.</p><p>We found that Indigenous children exhibited longer LOS, O<sub>2</sub> requirement and earlier time to hospital readmission than non-Indigenous children. The most likely reason why the latter aspects are different from our previous study <xref rid="pone.0074316-Bailey1" ref-type="bibr">[5]</xref> is because we excluded children managed in intensive care. In our cohort, Indigenous children were more likely to be readmitted for another respiratory illness. This is not surprising as Indigenous children in the NT are 5 times more likely to be hospitalised for pneumonia and influenza than non-Indigenous children <xref rid="pone.0074316-Valery1" ref-type="bibr">[43]</xref>. Whether readmission is related to the insult from bronchiolitis can only be postulated. Recurrent hospitalisation for respiratory illness is an independent risk factor for developing bronchiectasis and/or respiratory dysfunction in adulthood <xref rid="pone.0074316-Galobardes1" ref-type="bibr">[44]</xref>, <xref rid="pone.0074316-Tennant1" ref-type="bibr">[45]</xref>. In our region, bronchiectasis affects 1 in every 68 Indigenous children <xref rid="pone.0074316-Chang4" ref-type="bibr">[46]</xref>. In the follow up of our cohort, 6/61 (10%) Indigenous children (3 in azithromycin group, 3 in placebo group) have subsequently been diagnosed with bronchiectasis and an additional 4 children are awaiting chest scans.</p><p>The prevalence of readmission for a respiratory illness within 6-months in our trial was 21%; 70% had a wheezing illness. This was similar to the Turkish trial at 24% (53% were wheezing) <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref>. The two most common viruses found in our cohort, RSV and HRV have been implicated for ongoing wheezing <xref rid="pone.0074316-Mansbach1" ref-type="bibr">[47]</xref>&#x02013;<xref rid="pone.0074316-Kneyber2" ref-type="bibr">[50]</xref>. New Zealand data have also recently described high prevalence (70%) of on-going intermittent wheeze 12-months post hospitalisation with acute lower respiratory infections <xref rid="pone.0074316-Trenholme1" ref-type="bibr">[41]</xref>. In addition, wheezing and persistent cough can also be problematic post acute bronchiolitis <xref rid="pone.0074316-Tahan1" ref-type="bibr">[17]</xref>. Our trial (and the other published RCTs of macrolides for acute bronchiolitis) did not assess this, a known clinical research gap <xref rid="pone.0074316-Baumer1" ref-type="bibr">[7]</xref>, <xref rid="pone.0074316-McCallum1" ref-type="bibr">[51]</xref>.</p><p>Despite providing new data, there are other several limitations to our study, in addition to the concurrent use of antibiotics. Having older children increased the risk of including asthma prone children. We also did not limit to the first bronchiolitis admission. Removing the children with recurrent disease in a secondary analysis made no difference to study outcomes. As our study was limited to a single dose, it remains uncertain if any macrolides, or a longer macrolide treatment course, is beneficial in high risk children who do not receive any other antibiotics. Only having two sites, may also affect the generalisability of the results.</p></sec><sec id="s5"><title>Conclusion</title><p>In children hospitalised with moderate to severe bronchiolitis and requiring supplemental O<sub>2</sub>, we found that a large single dose of azithromycin (compared to placebo) did not have any clinical benefit to reduce LOS, duration of O<sub>2</sub> requirement or readmission rates within 6 months of hospital discharge. Azithromycin reduced the proportion of bacterial carriage, but had no significant effect on reducing proportion of viruses. Further research is required to determine whether earlier administration and longer duration of azithromycin is beneficial to improve the clinical and microbiological outcomes of acute bronchiolitis, associated co-morbidities and prevent ongoing respiratory morbidity in this population.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0074316.s001"><label>Checklist S1</label><caption><p>
<bold>CONSORT checklist.</bold>
</p><p>(PDF)</p></caption><media xlink:href="pone.0074316.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0074316.s002"><label>Protocol S1</label><caption><p>
<bold>Trial protocol.</bold>
</p><p>(PDF)</p></caption><media xlink:href="pone.0074316.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Lesley Versteegh, Clare Wilson, Susan Pizzutto, Kobi Schutz, Nerida Jacobsen and Louise Axford-Haines for assisting in data collection. We thank Kim Hare, Vanya Hampton, Jane Gaydon and Rebecca Rockett for processing the viral and bacterial samples. We thank Linda Ward for statistical support. We also thank the medical and nursing staff for their ongoing support and identifying the children for the study. We are grateful for all the children and families who participated in the study.</p></ack><ref-list><title>References</title><ref id="pone.0074316-Chang1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>AB</given-names></name>, <name><surname>Chang</surname><given-names>CC</given-names></name>, <name><surname>O'Grady</surname><given-names>K</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name> (<year>2009</year>) <article-title>Lower respiratory tract infections</article-title>. <source>Pediatr Clin North Am</source>
<volume>56</volume>: <fpage>1303</fpage>&#x02013;<lpage>1321</lpage>.<pub-id pub-id-type="pmid">19962023</pub-id></mixed-citation></ref><ref id="pone.0074316-Nair1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Nair</surname><given-names>H</given-names></name>, <name><surname>Nokes</surname><given-names>DJ</given-names></name>, <name><surname>Gessner</surname><given-names>BD</given-names></name>, <name><surname>Dherani</surname><given-names>M</given-names></name>, <name><surname>Madhi</surname><given-names>SA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</article-title>. <source>Lancet</source>
<volume>375</volume>: <fpage>1545</fpage>&#x02013;<lpage>1555</lpage>.<pub-id pub-id-type="pmid">20399493</pub-id></mixed-citation></ref><ref id="pone.0074316-Ducharme1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Ducharme</surname><given-names>FM</given-names></name> (<year>2011</year>) <article-title>Management of acute bronchiolitis</article-title>. <source>BMJ</source>
<volume>342</volume>: <fpage>d1658</fpage>.<pub-id pub-id-type="pmid">21471173</pub-id></mixed-citation></ref><ref id="pone.0074316-OGrady1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>O'Grady</surname><given-names>KA</given-names></name>, <name><surname>Lee</surname><given-names>KJ</given-names></name>, <name><surname>Carlin</surname><given-names>JB</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name>, <name><surname>Chang</surname><given-names>AB</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Increased risk of hospitalised acute lower respiratory infections in Australian Indigenous infants aged 5&#x02013;23 months following pneumococcal vaccination: a cohort study</article-title>. <source>Clinical Infectious Diseases</source>
<volume>50</volume>: <fpage>970</fpage>&#x02013;<lpage>978</lpage>.<pub-id pub-id-type="pmid">20192729</pub-id></mixed-citation></ref><ref id="pone.0074316-Bailey1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Bailey</surname><given-names>EJ</given-names></name>, <name><surname>Maclennan</surname><given-names>C</given-names></name>, <name><surname>Morris</surname><given-names>PS</given-names></name>, <name><surname>Kruske</surname><given-names>SG</given-names></name>, <name><surname>Brown</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Risks of severity and readmission of Indigenous and non-Indigenous children hospitalised for bronchiolitis</article-title>. <source>J Paediatr Child Health</source>
<volume>45</volume>: <fpage>593</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">19751375</pub-id></mixed-citation></ref><ref id="pone.0074316-Dawson1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Dawson</surname><given-names>K</given-names></name>, <name><surname>Kennedy</surname><given-names>D</given-names></name>, <name><surname>Asher</surname><given-names>I</given-names></name>, <name><surname>Cooper</surname><given-names>D</given-names></name>, <name><surname>Cooper</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1993</year>) <article-title>The management of acute bronchiolitis. Thoracic Society of Australia and New Zealand</article-title>. <source>J PaediatrChild Health</source>
<volume>29</volume>: <fpage>335</fpage>&#x02013;<lpage>337</lpage>.</mixed-citation></ref><ref id="pone.0074316-Baumer1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Baumer</surname><given-names>JH</given-names></name> (<year>2007</year>) <article-title>SIGN guideline on bronchiolitis in infants</article-title>. <source>Arch Dis Child EducPractEd</source>
<volume>92</volume>: <fpage>ep149</fpage>&#x02013;<lpage>ep151</lpage>.</mixed-citation></ref><ref id="pone.0074316-Subcommittee1"><label>8</label><mixed-citation publication-type="journal">
<collab>Subcommittee on Diagnosis and Management of Bronchiolitis</collab> (<year>2006</year>) <article-title>Diagnosis and Management of Bronchiolitis</article-title>. <source>Pediatrics</source>
<volume>118</volume>: <fpage>1774</fpage>&#x02013;<lpage>1793</lpage>.<pub-id pub-id-type="pmid">17015575</pub-id></mixed-citation></ref><ref id="pone.0074316-Zorc1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Zorc</surname><given-names>JJ</given-names></name>, <name><surname>Hall</surname><given-names>CB</given-names></name> (<year>2010</year>) <article-title>Bronchiolitis: recent evidence on diagnosis and management</article-title>. <source>Pediatrics</source>
<volume>125</volume>: <fpage>342</fpage>&#x02013;<lpage>349</lpage>.<pub-id pub-id-type="pmid">20100768</pub-id></mixed-citation></ref><ref id="pone.0074316-Jartti1"><label>10</label><mixed-citation publication-type="other">Jartti T, Jartti L, Ruuskanen O, Soderlund-Venermo M (2012) New respiratory viral infections. CurrOpinPulmMed.</mixed-citation></ref><ref id="pone.0074316-Brodzinski1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Brodzinski</surname><given-names>H</given-names></name>, <name><surname>Ruddy</surname><given-names>RM</given-names></name> (<year>2009</year>) <article-title>Review of new and newly discovered respiratory tract viruses in children</article-title>. <source>Pediatr EmergCare</source>
<volume>25</volume>: <fpage>352</fpage>&#x02013;<lpage>360</lpage>.</mixed-citation></ref><ref id="pone.0074316-ParanhosBaccala1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Paranhos-Baccala</surname><given-names>G</given-names></name>, <name><surname>Komurian-Pradel</surname><given-names>F</given-names></name>, <name><surname>Richard</surname><given-names>N</given-names></name>, <name><surname>Vernet</surname><given-names>G</given-names></name>, <name><surname>Lina</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Mixed respiratory virus infections</article-title>. <source>JClinVirol</source>
<volume>43</volume>: <fpage>407</fpage>&#x02013;<lpage>410</lpage>.</mixed-citation></ref><ref id="pone.0074316-Spurling1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Spurling</surname><given-names>GK</given-names></name>, <name><surname>Doust</surname><given-names>J</given-names></name>, <name><surname>Del Mar</surname><given-names>CB</given-names></name>, <name><surname>Eriksson</surname><given-names>L</given-names></name> (<year>2011</year>) <article-title>Antibiotics for bronchiolitis in children</article-title>. <source>CochraneDatabaseSystRev</source>
<volume>6</volume>: <fpage>CD005189</fpage>.</mixed-citation></ref><ref id="pone.0074316-Klein1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Klein</surname><given-names>JO</given-names></name> (<year>1997</year>) <article-title>History of macrolide use in pediatrics</article-title>. <source>Pediatr InfectDisJ</source>
<volume>16</volume>: <fpage>427</fpage>&#x02013;<lpage>431</lpage>.</mixed-citation></ref><ref id="pone.0074316-GiamarellosBourboulis1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name> (<year>2008</year>) <article-title>Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators</article-title>. <source>IntJ AntimicrobAgents</source>
<volume>31</volume>: <fpage>12</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="pone.0074316-Kneyber1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Kneyber</surname><given-names>MC</given-names></name>, <name><surname>van Woensel</surname><given-names>JB</given-names></name>, <name><surname>Uijtendaal</surname><given-names>E</given-names></name>, <name><surname>Uiterwaal</surname><given-names>CS</given-names></name>, <name><surname>Kimpen</surname><given-names>JL</given-names></name> (<year>2008</year>) <article-title>Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: A randomized equivalence trial</article-title>. <source>Pediatric Pulmonology</source>
<volume>43</volume>: <fpage>142</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">18085694</pub-id></mixed-citation></ref><ref id="pone.0074316-Tahan1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Tahan</surname><given-names>F</given-names></name>, <name><surname>Ozcan</surname><given-names>A</given-names></name>, <name><surname>Koc</surname><given-names>N</given-names></name> (<year>2007</year>) <article-title>Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial</article-title>. <source>European Respiratory Journal</source>
<volume>29</volume>: <fpage>91</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">17050564</pub-id></mixed-citation></ref><ref id="pone.0074316-Pinto1"><label>18</label><mixed-citation publication-type="other">Pinto LA, Pitrez PM, Luisi F, de Mello PP, Gerhardt M, <etal>et al</etal>.. (2012) Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial. JPediatr.</mixed-citation></ref><ref id="pone.0074316-Singleton1"><label>19</label><mixed-citation publication-type="other">Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, <etal>et al</etal>.. (2013) Indigenous Children from Three Countries with Non-Cystic Fibrosis Chronic Suppurative Lung Disease/Bronchiectasis Pediatric Pulmonology In press.</mixed-citation></ref><ref id="pone.0074316-Weber1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Weber</surname><given-names>MW</given-names></name>, <name><surname>Milligan</surname><given-names>P</given-names></name>, <name><surname>Giadom</surname><given-names>B</given-names></name>, <name><surname>Pate</surname><given-names>MA</given-names></name>, <name><surname>Kwara</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia JPediatr</article-title>. <volume>135</volume>: <fpage>683</fpage>&#x02013;<lpage>688</lpage>.</mixed-citation></ref><ref id="pone.0074316-Ghafoor1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Ghafoor</surname><given-names>A</given-names></name>, <name><surname>Nomani</surname><given-names>NK</given-names></name>, <name><surname>Ishaq</surname><given-names>Z</given-names></name>, <name><surname>Zaidi</surname><given-names>SZ</given-names></name>, <name><surname>Anwar</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>1990</year>) <article-title>Diagnoses of acute lower respiratory tract infections in children in Rawalpindi and Islamabad, Pakistan</article-title>. <source>Rev Infect Dis</source>
<volume>12</volume> Suppl 8<fpage>S907</fpage>&#x02013;<lpage>914</lpage>.<pub-id pub-id-type="pmid">2270413</pub-id></mixed-citation></ref><ref id="pone.0074316-OGrady2"><label>22</label><mixed-citation publication-type="journal">
<name><surname>O'Grady</surname><given-names>KA</given-names></name>, <name><surname>Chang</surname><given-names>AB</given-names></name> (<year>2010</year>) <article-title>Lower respiratory infections in Australian Indigenous children</article-title>. <source>J PaediatrChild Health</source>
<volume>46</volume>: <fpage>461</fpage>&#x02013;<lpage>465</lpage>.</mixed-citation></ref><ref id="pone.0074316-Torzillo1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Torzillo</surname><given-names>P</given-names></name>, <name><surname>Dixon</surname><given-names>J</given-names></name>, <name><surname>Manning</surname><given-names>K</given-names></name>, <name><surname>Hutton</surname><given-names>S</given-names></name>, <name><surname>Gratten</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Etiology of acute lower respiratory tract infection in Central Australian Aboriginal children</article-title>. <source>PediatrInfectDisJ</source>
<volume>18</volume>: <fpage>714</fpage>&#x02013;<lpage>721</lpage>.</mixed-citation></ref><ref id="pone.0074316-Bezerra1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Bezerra</surname><given-names>PG</given-names></name>, <name><surname>Britto</surname><given-names>MC</given-names></name>, <name><surname>Correia</surname><given-names>JB</given-names></name>, <name><surname>Duarte</surname><given-names>MC</given-names></name>, <name><surname>Fonceca</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Viral and atypical bacterial detection in acute respiratory infection in children under five years</article-title>. <source>PLoSONE</source>
<volume>6</volume>: <fpage>e18928</fpage>.</mixed-citation></ref><ref id="pone.0074316-Didierlaurent1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Didierlaurent</surname><given-names>A</given-names></name>, <name><surname>Goulding</surname><given-names>J</given-names></name>, <name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Snelgrove</surname><given-names>R</given-names></name>, <name><surname>Low</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection</article-title>. <source>JExpMed</source>
<volume>205</volume>: <fpage>323</fpage>&#x02013;<lpage>329</lpage>.</mixed-citation></ref><ref id="pone.0074316-SmithVaughan1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Smith-Vaughan</surname><given-names>H</given-names></name>, <name><surname>Byun</surname><given-names>R</given-names></name>, <name><surname>Nadkarni</surname><given-names>M</given-names></name>, <name><surname>Jacques</surname><given-names>NA</given-names></name>, <name><surname>Hunter</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Measuring nasal bacterial load and its association with otitis media</article-title>. <source>BMC Ear Nose Throat Disord</source>
<volume>6</volume>: <fpage>10</fpage>.<pub-id pub-id-type="pmid">16686940</pub-id></mixed-citation></ref><ref id="pone.0074316-Chang2"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>AB</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name>, <name><surname>Boyce</surname><given-names>NC</given-names></name>, <name><surname>White</surname><given-names>AV</given-names></name>, <name><surname>Stewart</surname><given-names>PA</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Zinc and Vitamin-A supplementation in Indigenous children hospitalised with episodes of lower respiratory tract infection: a randomised controlled trial</article-title>. <source>The Medical Journal of Australia</source>
<volume>184</volume>: <fpage>107</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">16460294</pub-id></mixed-citation></ref><ref id="pone.0074316-Stubbs1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Stubbs</surname><given-names>E</given-names></name>, <name><surname>Hare</surname><given-names>K</given-names></name>, <name><surname>Wilson</surname><given-names>C</given-names></name>, <name><surname>Morris</surname><given-names>P</given-names></name>, <name><surname>Leach</surname><given-names>AJ</given-names></name> (<year>2005</year>) <article-title>Streptococcus pneumoniae and noncapsular Haemophilus influenzae nasal carriage and hand contamination in children: a comparison of two populations at risk of otitis media</article-title>. <source>Pediatr InfectDisJ</source>
<volume>24</volume>: <fpage>423</fpage>&#x02013;<lpage>428</lpage>.</mixed-citation></ref><ref id="pone.0074316-Hare1"><label>29</label><mixed-citation publication-type="other">Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, <etal>et al</etal>.. (2010) Respiratory Bacterial Pathogens in the Nasopharynx and Lower Airways of Australian Indigenous Children with Bronchiectasis. J Pediatr.</mixed-citation></ref><ref id="pone.0074316-Arden1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Arden</surname><given-names>KE</given-names></name>, <name><surname>McErlean</surname><given-names>P</given-names></name>, <name><surname>Nissen</surname><given-names>MD</given-names></name>, <name><surname>Sloots</surname><given-names>TP</given-names></name>, <name><surname>Mackay</surname><given-names>IM</given-names></name> (<year>2006</year>) <article-title>Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections</article-title>. <source>J Med Virol</source>
<volume>78</volume>: <fpage>1232</fpage>&#x02013;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">16847968</pub-id></mixed-citation></ref><ref id="pone.0074316-Chang3"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>AB</given-names></name>, <name><surname>Clark</surname><given-names>R</given-names></name>, <name><surname>Acworth</surname><given-names>JP</given-names></name>, <name><surname>Petsky</surname><given-names>HL</given-names></name>, <name><surname>Sloots</surname><given-names>TP</given-names></name> (<year>2009</year>) <article-title>The impact of viral respiratory infection on the severity and recovery from an asthma exacerbation</article-title>. <source>Pediatr InfectDis J</source>
<volume>28</volume>: <fpage>290</fpage>&#x02013;<lpage>294</lpage>.</mixed-citation></ref><ref id="pone.0074316-Arden2"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Arden</surname><given-names>KE</given-names></name>, <name><surname>Chang</surname><given-names>AB</given-names></name>, <name><surname>Lambert</surname><given-names>SB</given-names></name>, <name><surname>Nissen</surname><given-names>MD</given-names></name>, <name><surname>Sloots</surname><given-names>TP</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Newly identified respiratory viruses in children with asthma exacerbation not requiring admission to hospital</article-title>. <source>J Med Virol</source>
<volume>82</volume>: <fpage>1458</fpage>&#x02013;<lpage>1461</lpage>.<pub-id pub-id-type="pmid">20572080</pub-id></mixed-citation></ref><ref id="pone.0074316-Hare2"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Hare</surname><given-names>KM</given-names></name>, <name><surname>Morris</surname><given-names>P</given-names></name>, <name><surname>Smith-Vaughan</surname><given-names>H</given-names></name>, <name><surname>Leach</surname><given-names>AJ</given-names></name> (<year>2008</year>) <article-title>Random colony selection versus colony morphology for detection of multiple pneumococcal serotypes in nasopharyngeal swabs</article-title>. <source>Pediatr Infect Dis J</source>
<volume>27</volume>: <fpage>178</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">18174871</pub-id></mixed-citation></ref><ref id="pone.0074316-Douglas1"><label>34</label><mixed-citation publication-type="other">Douglas Altman (1989) DMTBS Statistics with Confidence. Bristol: BMJ books. p.74&#x02013;79.</mixed-citation></ref><ref id="pone.0074316-Sugiyama1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Sugiyama</surname><given-names>K</given-names></name>, <name><surname>Shirai</surname><given-names>R</given-names></name>, <name><surname>Mukae</surname><given-names>H</given-names></name>, <name><surname>Ishimoto</surname><given-names>H</given-names></name>, <name><surname>Nagata</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells</article-title>. <source>Clin Exp Immunol</source>
<volume>147</volume>: <fpage>540</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">17302905</pub-id></mixed-citation></ref><ref id="pone.0074316-Blasi1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Blasi</surname><given-names>F</given-names></name>, <name><surname>Cazzola</surname><given-names>M</given-names></name>, <name><surname>Tarsia</surname><given-names>P</given-names></name>, <name><surname>Cosentini</surname><given-names>R</given-names></name>, <name><surname>Aliberti</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Azithromycin and lower respiratory tract infections</article-title>. <source>ExpertOpinPharmacother</source>
<volume>6</volume>: <fpage>2335</fpage>&#x02013;<lpage>2351</lpage>.</mixed-citation></ref><ref id="pone.0074316-Leach1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Leach</surname><given-names>AJ</given-names></name>, <name><surname>Boswell</surname><given-names>JB</given-names></name>, <name><surname>Asche</surname><given-names>V</given-names></name>, <name><surname>Nienhuys</surname><given-names>TG</given-names></name>, <name><surname>Mathews</surname><given-names>JD</given-names></name> (<year>1994</year>) <article-title>Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants</article-title>. <source>Pediatr Infect Dis J</source>
<volume>13</volume>: <fpage>983</fpage>&#x02013;<lpage>989</lpage>.<pub-id pub-id-type="pmid">7845752</pub-id></mixed-citation></ref><ref id="pone.0074316-OGrady3"><label>38</label><mixed-citation publication-type="journal">
<name><surname>O'Grady</surname><given-names>KA</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name>, <name><surname>Chang</surname><given-names>AB</given-names></name> (<year>2010</year>) <article-title>Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life</article-title>. <source>MedJAust</source>
<volume>192</volume>: <fpage>586</fpage>&#x02013;<lpage>590</lpage>.</mixed-citation></ref><ref id="pone.0074316-Bisgaard1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Bisgaard</surname><given-names>H</given-names></name>, <name><surname>Hermansen</surname><given-names>MN</given-names></name>, <name><surname>Bonnelykke</surname><given-names>K</given-names></name>, <name><surname>Stokholm</surname><given-names>J</given-names></name>, <name><surname>Baty</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study</article-title>. <source>BMJ</source>
<volume>341</volume>: <fpage>c4978</fpage>.<pub-id pub-id-type="pmid">20921080</pub-id></mixed-citation></ref><ref id="pone.0074316-Singleton2"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Singleton</surname><given-names>RJ</given-names></name>, <name><surname>Bruden</surname><given-names>D</given-names></name>, <name><surname>Bulkow</surname><given-names>LR</given-names></name>, <name><surname>Varney</surname><given-names>G</given-names></name>, <name><surname>Butler</surname><given-names>JC</given-names></name> (<year>2006</year>) <article-title>Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season</article-title>. <source>Pediatr InfectDis J</source>
<volume>25</volume>: <fpage>1116</fpage>&#x02013;<lpage>1122</lpage>.</mixed-citation></ref><ref id="pone.0074316-Trenholme1"><label>41</label><mixed-citation publication-type="other">Trenholme AA, Byrnes CA, McBride C, Lennon DR, Chan-Mow F, <etal>et al</etal>.. (2012) Respiratory health outcomes 1 year after admission with severe lower respiratory tract infection. Pediatr Pulmonol.</mixed-citation></ref><ref id="pone.0074316-Grimwood1"><label>42</label><mixed-citation publication-type="other">Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, <etal>et al</etal>.. (2008) Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. EpidemiolInfect: 1&#x02013;9.</mixed-citation></ref><ref id="pone.0074316-Valery1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Valery</surname><given-names>PC</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name>, <name><surname>Mulholland</surname><given-names>EK</given-names></name>, <name><surname>Boyce</surname><given-names>NC</given-names></name>, <name><surname>Purdie</surname><given-names>DM</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>A hospital-based case-control study of bronchiectasis in Indigenous children in Central Australia</article-title>. <source>Pediatr Infect Dis J</source>
<volume>23</volume>: <fpage>902</fpage>&#x02013;<lpage>908</lpage>.<pub-id pub-id-type="pmid">15602188</pub-id></mixed-citation></ref><ref id="pone.0074316-Galobardes1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Galobardes</surname><given-names>B</given-names></name>, <name><surname>McCarron</surname><given-names>P</given-names></name>, <name><surname>Jeffreys</surname><given-names>M</given-names></name>, <name><surname>vey-Smith</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Medical history of respiratory disease in early life relates to morbidity and mortality in adulthood</article-title>. <source>Thorax</source>
<volume>63</volume>: <fpage>423</fpage>&#x02013;<lpage>429</lpage>.<pub-id pub-id-type="pmid">18276724</pub-id></mixed-citation></ref><ref id="pone.0074316-Tennant1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Tennant</surname><given-names>PW</given-names></name>, <name><surname>Gibson</surname><given-names>GJ</given-names></name>, <name><surname>Pearce</surname><given-names>MS</given-names></name> (<year>2008</year>) <article-title>Lifecourse predictors of adult respiratory function: results from the Newcastle Thousand Families Study</article-title>. <source>Thorax</source>
<volume>63</volume>: <fpage>823</fpage>&#x02013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">18408051</pub-id></mixed-citation></ref><ref id="pone.0074316-Chang4"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>AB</given-names></name>, <name><surname>Grimwood</surname><given-names>K</given-names></name>, <name><surname>Mulholland</surname><given-names>EK</given-names></name>, <name><surname>Torzillo</surname><given-names>PJ</given-names></name> (<year>2002</year>) <collab>Working Group on Indigenous Paediatric Respiratory Health</collab> (<year>2002</year>) <article-title>Bronchiectasis in indigenous children in remote Australian communities</article-title>. <source>Med J Aust</source>
<volume>177</volume>: <fpage>200</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">12175325</pub-id></mixed-citation></ref><ref id="pone.0074316-Mansbach1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Mansbach</surname><given-names>JM</given-names></name>, <name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name> (<year>2009</year>) <article-title>Respiratory viruses in bronchiolitis and their link to recurrent wheezing and asthma</article-title>. <source>Clin Lab Med</source>
<volume>29</volume>: <fpage>741</fpage>&#x02013;<lpage>755</lpage>.<pub-id pub-id-type="pmid">19892232</pub-id></mixed-citation></ref><ref id="pone.0074316-Midulla1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Midulla</surname><given-names>F</given-names></name>, <name><surname>Pierangeli</surname><given-names>A</given-names></name>, <name><surname>Cangiano</surname><given-names>G</given-names></name>, <name><surname>Bonci</surname><given-names>E</given-names></name>, <name><surname>Salvadei</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up</article-title>. <source>EurRespirJ</source>
<volume>39</volume>: <fpage>396</fpage>&#x02013;<lpage>402</lpage>.</mixed-citation></ref><ref id="pone.0074316-Bosis1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Bosis</surname><given-names>S</given-names></name>, <name><surname>Esposito</surname><given-names>S</given-names></name>, <name><surname>Niesters</surname><given-names>HG</given-names></name>, <name><surname>Zuccotti</surname><given-names>GV</given-names></name>, <name><surname>Marseglia</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences</article-title>. <source>ClinMicrobiolInfect</source>
<volume>14</volume>: <fpage>677</fpage>&#x02013;<lpage>684</lpage>.</mixed-citation></ref><ref id="pone.0074316-Kneyber2"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Kneyber</surname><given-names>MCJ</given-names></name>, <name><surname>Steyerberg</surname><given-names>EW</given-names></name>, <name><surname>de</surname><given-names>GR</given-names></name>, <name><surname>Moll</surname><given-names>HA</given-names></name> (<year>2000</year>) <article-title>Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review</article-title>. <source>Acta Paediatr</source>
<volume>89</volume>: <fpage>654</fpage>&#x02013;<lpage>660</lpage>.<pub-id pub-id-type="pmid">10914957</pub-id></mixed-citation></ref><ref id="pone.0074316-McCallum1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>McCallum</surname><given-names>GB</given-names></name>, <name><surname>Morris</surname><given-names>PS</given-names></name>, <name><surname>Chang</surname><given-names>AB</given-names></name> (<year>2012</year>) <article-title>Antibiotics for persistent cough or wheeze following acute bronchiolitis in children</article-title>. <source>Cochrane Database Syst Rev</source>
<volume>12</volume>: <fpage>CD009834</fpage>.<pub-id pub-id-type="pmid">23235681</pub-id></mixed-citation></ref></ref-list></back></article>